PeptideChemSF said:They are two different exemptions from the same federal requirements and they buy different things.
I read this differently from PeptideChemSF, on substance rather than tone. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.
Dr.PeteFamMed said:My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
Beyond-use dating (BUD) for compounded supply compounded products:
Lyophilized (unreconstituted): typically 6 months from compounding date
Reconstituted with BAC water: typically 28-30 days refrigerated
Reconstituted with sterile water: typically 24 hours (no preservative!)
Always use BAC water for multi-dose vials. Sterile water has no preservative and supports bacterial growth after first puncture. This is a common and potentially dangerous mistake.
NurseKim_ATL said:A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $1098 | FDA-approved | N/A (pharma) |
| 503B Compounding | $178 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $128 | Patient-specific | Varies |
| Research peptide | $63 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne thing that is still open after josh_phd_bmore’s answer:
Why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission?
Reporting back.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.